GLAND PHARMA Results Analysis-Q4FY26

$GLAND Operating Revenue for Q4FY26 is Rs. 1,743 Crs. 22.31% growth YoY, Total Income is Rs. 1,854 Crs., 26.23% growth YoY, Gross Profit is Rs. 1,151 Crs., 22.89% growth YoY, EBITDA is Rs. 513 Crs., 47.63% growth YoY, EBITDA Margin is 29.44% declined by 505 Basis points YoY, PBT Rs. 506 Crs. 75.42% growth YoY, PAT Rs. 367 Crs. 96.57% growth YoY. On QoQ basis Op. Revenue is up by 2.8%, Total Income is up by 5.44%, Gross Profit is up by 2.93%, EBITDA is up by 17.97%, PBT is up by 39.67% and PAT is also up by 40.23%. Very strong quarter and a year” with “highest ever quarterly revenues and EBITDA.” Key Q4 growth contributors (management): “new product launches, including Dalbavancin,” “higher volumes from recently secured tender wins,” “continued ramp-up in key products,” and “improving capacity utilization.” Gland: FY27 target “mid-single digit, high single-digit EBITDA, management expects ~15% CAGR over “the next four years” CDMO is now framed as the key strategic pillar. CDMO = 46% of total revenues (group) (because Cenexi is 100% CDMO), and management cited 28% CDMO growth at group level.